Clinical trial
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00080327 · Otsuka Pharmaceutical Development & Commercialization, Inc., Industry · Completed
Key facts
| NCT number | NCT00080327 |
|---|---|
| Title | Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia |
| Official title | A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia |
| Lead sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc., Industry |
| Collaborators | Otsuka America Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Aripiprazole, Placebo |
| Enrollment | 370 |
| Start date | Nov 1, 2003 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Mar 30, 2004 |
| Last update posted | Nov 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: